New target for HIV vaccine found
The fusion peptide is a new region of interest for HIV vaccine development, researchers say.
Some people infected with HIV naturally produce broadly neutralising antibodies (bnAbs) against the virus. One strategy for vaccine development is to elicit the production of specific bnAbs from uninfected individuals, which would protect against HIV infection.
US researchers, reporting in Science (online, 13 May 2016), studied an HIV-infected person who produced potent bnAbs, but they hadn’t yet been able to identify the region of the virus recognised by the antibodies.
By isolating the most potent bnAb from this person, they found that it binds to the viral fusion peptide of HIV-1. This region plays a vital role in allowing the virus to gain entry to cells by helping it fuse with the cell membrane.
Citation: Clinical Pharmacist DOI: 10.1211/CP.2016.20201162
Recommended from Pharmaceutical Press
Pharmaceutical Press is the publishing division of the Royal Pharmaceutical Society, and is a leading provider of authoritative pharmaceutical information used throughout the world.Visit rpharms.com